Big Movers in Focus: Newmont Mining Corporation (NYSE:NEM), FireEye (NASDAQ:FEYE), Covisint Corporation (NASDAQ:COVS), American Apparel (NYSEMKT:APP), Incyte Corporation (NASDAQ:INCY)


Newmont Mining Corporation (NYSE:NEM) has been given a “BBB” credit rating by Morningstar. The investment research firm’s “BBB” rating suggests that the company is a moderate default risk. They also gave their stock a four star rating. On Monday shares of Newmont Mining Corporation (NYSE:NEM) closed at $24.49. Company’s sales growth for last 5 years was 6.30%.

On 19 January FireEye, Inc. (NASDAQ:FEYE) announced that it has been awarded the UK Government’s new Cyber Essentials Scheme accreditation. FireEye, Inc. (NASDAQ:FEYE) has 1.00% insider ownership while its institutional ownership stands at 61.80%. In last trading activity company’s stock closed at $35.39.

Covisint Corporation (NASDAQ:COVS) will release financial results for its third quarter fiscal 2015 – ended December 31, 2014 – after the U.S. stock market close on Tuesday, February 10, 2015. On last trading day Covisint Corporation (NASDAQ:COVS) advanced 0.42% to close at $2.41. Its volatility for the week is 4.98% while volatility for the month is 5.69%. Covisint Corporation (NASDAQ:COVS) monthly performance is -9.06%.

On 13 January American Apparel, Inc. (NYSEMKT:APP) has been named one of the top 15 suppliers for the United States Department of Defense. The manufacturing company, who makes and supplies uniforms for the military, was given the Gold Star Award by the Defense Logistics Agency. American Apparel, Inc. (NYSEMKT:APP) has 2.30% insider ownership while its institutional ownership stands at 8.50%. In last trading activity company’s stock closed at $0.86.

On 23 January Incyte Corporation (NASDAQ:INCY) has earned a $25 million milestone payment from Novartis (NYSE: NVS). This payment was triggered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopting a positive opinion for Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Incyte expects to record this amount as contract revenue, and receive the $25 million payment, in the first quarter of 2015. On last trading day Incyte Corporation (NASDAQ:INCY) advanced 3.82% to close at $82.95. Its volatility for the week is 5.02% while volatility for the month is 4.09%. INCY’s sales growth for past 5 years was 146.50% and its EPS growth for past 5 years was 22.40%. Incyte Corporation (NASDAQ:INCY) monthly performance is 19.22%.


Leave a Reply

Your email address will not be published. Required fields are marked *